Table 4 CK levels and clinical features of 14 patients with Guillain–Barré syndrome with elevated CK levels
From: Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels
Patient No. | Age/sex | CK | Cranial nerve involvement | Limb weakness | CMAP amplitude (mV) Right median nerve | Treatment | Disability | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Time until first elevation (days) | Time until peak (days) | Level at peak (U/L) | Arm or leg dominant | Proximal or distal dominant | Symmetric or asymmetric | Time until nadir (days) | At nadir (HG) | 14 days after onset (HG) | 28 days after onset (HG) | |||||
1 | 20–29/M | 4 | 4 | 1937 | None | Arm dominant | Distal dominant | Symmetric | 0.5 | IVIG | 4 | 2 | 1 | 1 |
2 | 30–39/M | 9 | 9 | 1264 | None | No dominance | No dominance | Symmetric | 6.2 | IVIG | 2 | 3 | 2 | 1 |
3 | 30–39/M | 11 | 11 | 795 | None | Arm dominant | Distal dominant | Symmetric | 3.2 | IVIG | 11 | 2 | 2 | 1 |
4 | 20–29/M | 16 | 24 | 591 | None | No dominance | No dominance | Symmetric | 7.1 | IVIG | 15 | 2 | 2 | 1 |
5 | 30–39/M | 11 | 14 | 550 | Ophthalmoplegia, Facial weakness, bulbar weakness | No dominance | Distal dominant | Symmetric | 7 | IVIG + steroid pulse | 4 | 4 | 2 | 2 |
6 | 40–49/M | 2 | 10 | 515 | None | Arm dominant | Distal dominant | Symmetric | 2.5 | IVIG | 4 | 2 | 2 | 2 |
7 | 30–39/M | 9 | 9 | 433 | None | Arm dominant | Distal dominant | Symmetric | 5.2 | None | 6 | 2 | 2 | 0 |
8 | 30–39/M | 25 | 28 | 429 | Bulbar weakness | Leg dominant | No dominance | Symmetric | 0.5 | IVIG + plasma exchange | 10 | 5 | 5 | 5 |
9 | 50–59/M | 7 | 7 | 402 | None | Arm dominant | No dominance | Asymmetric | 7.5 | IVIG | 12 | 1 | 1 | 1 |
10 | 50–59/M | 2 | 4 | 396 | None | No dominance | Distal dominant | Asymmetric | 7 | IVIG | 5 | 4 | 1 | 1 |
11 | 40–49/F | 6 | 10 | 351 | None | No dominance | No dominance | Symmetric | 7.8 | IVIG | 8 | 2 | 1 | 1 |
12 | 40–49/M | 3 | 5 | 319 | None | No dominance | No dominance | Symmetric | 8.8 | IVIG | 4 | 2 | 2 | 1 |
13 | 40–49/M | 10 | 16 | 300 | None | No dominance | No dominance | Symmetric | 2.5 | IVIG | 4 | 4 | 3 | 2 |
14 | 60–69/F | 5 | 5 | 288 | None | No dominance | Distal dominant | Symmetric | 7.5 | IVIG | 4 | 3 | 2 | 1 |